Investigational drug · Phase 3
Zilebesiran
Also called: ALN-AGT01
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Hypertension, High Cardiovascular Risk, High Risk Cardiovascular Disease.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
2 still active
All registered trials
7
Any phase or sponsor naming "Zilebesiran"
First trial start
2024
Feb 29, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Zilebesiran", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hypertension
- High Cardiovascular Risk
- High Risk Cardiovascular Disease
- Mild to Moderate Hypertension
Approved drugs for the same conditions: High blood pressure (hypertension) · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "Zilebesiran" as an intervention, largest first.
- Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular DiseasePivotal-lookingRecruiting
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
NCT07181109 · 11,000 participants (planned) · Start Sep 6, 2025 · Primary completion Sep 23, 2030
Drug: Zilebesiran; Placebo · For: High Risk Cardiovascular Disease; Hypertension; High Cardiovascular Risk
Sites: Birmingham, Alabama; Fairhope, Alabama; Foley, Alabama · 1,226 sites in all
- Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)Pivotal-lookingCompleted
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
NCT05103332 · 663 participants · Start Nov 5, 2021 · Primary completion Dec 11, 2023
Drug: Indapamide; Amlodipine and 3 more · For: Hypertension
Sites: Mesa, Arizona; Tempe, Arizona; Bell Gardens, California · 110 sites in all
- A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate HypertensionPivotal-lookingCompleted
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
NCT04936035 · 394 participants · Start Jul 7, 2021 · Primary completion Apr 4, 2023
Drug: Placebo; ALN-AGT01 · For: Hypertension
Sites: Birmingham, Alabama; Tempe, Arizona; Beverly Hills, California · 75 sites in all
- Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)Pivotal-lookingCompleted
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
NCT06272487 · 375 participants · Start Feb 29, 2024 · Primary completion Jun 19, 2025
Drug: Zilebesiran; Placebo · For: High Cardiovascular Risk; Hypertension
Sites: Alexander City, Alabama; Daphne, Alabama; Foley, Alabama · 195 sites in all
- A Study to Evaluate ALN-AGT01 in Patients With HypertensionPivotal-lookingCompleted
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
NCT03934307 · 124 participants · Start May 1, 2019 · Primary completion Apr 20, 2022
Drug: ALN-AGT01; ALN-AGT01-Matching Placebo and 2 more · For: Hypertension
Sites: Edinburgh, United Kingdom; London, United Kingdom; Manchester, United Kingdom
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
NCT07553442 · 93 participants (planned) · Start Apr 27, 2026 · Primary completion Apr 1, 2028
Drug: ALN-AGT01 RVR; Placebo and 1 more · For: Hypertension
Sites: Lake Forest, California; Tampa, Florida; Savannah, Georgia
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
NCT06423352 · 36 participants · Start Jun 5, 2024 · Primary completion Jul 17, 2025
Drug: Zilebesiran; Placebo · For: Mild to Moderate Hypertension
Sites: Fukuoka, Japan; Osaka, Japan; Tokyo, Japan
Newest research
PubMed records naming it or its code names, newest first.
- Emerging therapeutics in hypertension: Evidence, clinical readiness, and implementation.
Tavethia J, Shivanne Gowda D, Mehta S, et al. · Curr Probl Cardiol 2027
- Correspondence: Reply to "Heterogeneity in dosages and treatment conditions forms a blurred picture of the results".
Hussain M, Hassan M, Sohaib A, et al. · Eur J Clin Pharmacol 2026
- Heterogeneity in dosages and treatment conditions forms a blurred picture of the results.
Jumani A, Shakeel N, Bai J, et al. · Eur J Clin Pharmacol 2026
- RNA-Targeted Therapeutics in Cardiovascular Risk Reduction: From Gene Silencing to Precision Cardiology.
Karim A, Binte Imran S, Yousuf YM, et al. · Cardiol Rev 2026
- Are Injectable Antihypertensives the Answer to Improving Blood Pressure Control: SiRNAs and Antisense Oligonucleotide Agents.
Sabouret P, Giamundo DM, Ibrahim A, et al. · Curr Cardiol Rep 2026
- Angiotensinogen as a molecular hub in interorgan communication.
Zhou J, Ye X, Wang Y, et al. · J Transl Med 2026
Also in development for Hypertension
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- CagriSemaCagrilintide B and Semaglutide IPhase 36 trials
Novo Nordisk · Obesity, Diabetes Mellitus, Type 2, Hypertension
- lorundrostatPhase 35 trials
Mineralys Therapeutics Inc. · Hypertension, Obstructive Sleep Apnea, Chronic Kidney Disease
- VCT220CX11Phase 35 trials
Vincentage Pharma Co., Ltd · Obesity, Type 2 Diabetes Mellitus (DM), Hypertension
- VicadrostatBI 690517Phase 35 trials
Boehringer Ingelheim · Heart Failure, Diabetes Mellitus, Type 2, Hypertension
- ClazakizumabLY5724886, CSL300Phase 32 trials
Eli Lilly · Atherosclerosis, Cardiovascular Disease, Obesity
- DWC202314Phase 32 trials
Daewoong Pharmaceutical Co. LTD. · Essential Hypertension, Hypertension
- DWC202314PPhase 32 trials
Daewoong Pharmaceutical Co. LTD. · Essential Hypertension, Hypertension
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Alnylam Pharmaceuticals.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.